20000679?-6

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :
C07D 413/14, 417/14, C07F 9/6558, C07D 413/12, 487/08, 451/02, A61K 31/42, 31/44 // (C07D 487/08, 209:00, 209:00)

A2

(11) International Publication Number: WO 99/64417

(43) International Publication Date: 16 December 1999 (16.12.99)

(21) International Application Number: PCT/GB99/01753

(22) International Filing Date: 3 June 1999 (03.06.99)

(30) Priority Data:

9812021.5	5 June 1998 (05.06.98)	GB
9820164.3	17 September 1998 (17.09.98)	GB
9826066.4	28 November 1998 (28.11.98)	GB

(71) Applicant *(for all designated States except US)*: ZENECA LIMITED [GB/GB]; 15 Stanhope Gate, London W1Y 6LN (GB).

(72) Inventor; and

(75) Inventor/Applicant *(for US only)*: GRAVESTOCK, Michael, Barry [GB/GB]; Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).


(74) Agent: BRYANT, Tracey; Zeneca Pharmaceuticals, Intellectual Property Dept., Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).


Published

Without international search report and to be republished upon receipt of that report.


(54) Title: OXAZOLIDINONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM




(I)



(Q1)



(Q2)



(TC5)

(57) Abstract

Compounds of formula (I), or a pharmaceutically–acceptable salt, or an in–vivo–hydrolysable ester thereof, wherein, for example, X is –O– or –S–; HET is an optionally substituted C–linked 5–membered heteroaryl ring containing 2 to 4 heteroatoms independently selected from N, O and S; Q is selected from, for example, formulae (Q1) and (Q2); R^2 and R^3 are independently hydrogen or fluoro; T is selected from a range of groups, for example, an N–linked (fully unsaturated) 5–membered heteroaryl ring system or a group of formula (TC5) wherein Rc is, for example, $R^{13}CO$–, $R^{13}SO_2$– or $R^{13}CS$–; wherein R^{13} is, for example, optionally substituted (1–10C)alkyl or $R^{14}C(O)O$(1–6C)alkyl wherein R^{14} is optionally substituted (1–10C)alkyl; are useful as antibacterial agents; and processes for their manufacture and pharmaceutical compositions containing them are described.